

Titre de l'annonce	<h1 style="text-align: center;">Therapy for neuromuscular diseases</h1>
Ville	Lyon
Pays	France
Texte de l'offre	<p>Job offers: 3 engineers</p> <p>The Bomont laboratory, and the partner Puccio are seeking highly motivated candidates in the development of therapy for neuromuscular diseases.</p> <p>Science. Bomont laboratory has a long-lasting expertise in the fatal neuromuscular disease called Giant Axonal Neuropathy (GAN)¹. The team identified the defective gene², which encodes for the Gigaxonin-E3 ligase and modeled the disease in mouse and zebrafish, to unravel pivotal roles of Gigaxonin in cytoskeleton architecture³, autophagy maturation⁴ and motoneuron specification⁵. With robust animal models in hands, and the identification of therapeutic candidates, the team aims to conduct a dual preclinical study for GAN: using pharmacological and gene therapy approaches. This translational project will benefit from the expertise of the Puccio team, which succeeded in developing gene therapy programs for Friedreich Ataxia⁶⁻⁸.</p> <p>Ref: 1. Lescouzères and Bomont. <i>Front Physiol.</i> (2020); 2. Bomont et al., <i>Nat Genet</i> (2000); 3. Mahammad et al., <i>J Clin Invest</i> (2013)-leading group: RD. Goldman; 4. Scrivo et al., <i>Nat Commun</i> (2019); 5. Arribat, Mysiak et al., <i>J Clin Invest</i> (2019); 6. Perdomini et al., <i>Nat Med.</i> (2014); Piguet et al., <i>Mol Ther.</i> (2018); Belbellaa et al., <i>Hum Mol Genet.</i> (2019).</p> <p>Profiles. 3 engineers (Bomont & Puccio); will work in close collaboration with other members of the teams. Mandatory for all: curious, enthusiastic & team player; prior experience with mice. Engineer 1 expertise: behaviour, preferably sensory-motor tests; cell culture and biochemical skills are assets but not required. Engineer 2 expertise: histopathology; cell</p>

	<p>culture/immunofluorescence is an asset. Engineer 3 expertise: skills in molecular biology techniques; immunofluorescence and histopathology are assets but not required. French speaking is NOT a requirement.</p> <p>When/how to apply. URGENT: starting date in September 2021. Please send your application in a SINGLE 3 page-long pdf, including you CV, summary of your previous research experiences, and contact information of 2-3 references to: pascale.bomont@inserm.fr and helene.puccio@inserm.fr</p> <p>Where. Bomont and Puccio teams are both at the NeuroMyoGene institute, located in the Rockefeller campus, in the highly dynamic and international city of Lyon, France. Lyon is considered as one of the most attractive metropolises in Europe, with a strong signature in biological science, architecture, & gastronomy.</p> <p>Link to Bomont webpage: https://www.inmg.fr/bomont/?lang=en Link to Puccio webpage: https://www.inmg.fr/puccio/?lang=en</p>
Date de fin de publication :	31/08/2021
Type d'emploi	Ingénieur - Engineer
Date début de fonction	01/09/2021
Information contact	pascale.bomont@inserm.fr



« Therapy for Giant Axonal Neuropathy »

Job offers: engineers

The Bomont laboratory, and the partner Puccio are seeking highly motivated candidates in the development of therapy for neuromuscular diseases.

Science. Bomont laboratory has a long-lasting expertise in the fatal neuromuscular disease called Giant Axonal Neuropathy (GAN)¹. The team identified the defective gene², which encodes for the Gigaxonin-E3 ligase and modeled the disease in mouse and zebrafish, to unravel pivotal roles of Gigaxonin in cytoskeleton architecture³, autophagy maturation⁴ and motoneuron specification⁵. With robust animal models in hands, and the identification of therapeutic candidates, the team aims to conduct a dual preclinical study for GAN: using pharmacological and gene therapy approaches. This translational project will benefit from the expertise of the Puccio team, which succeeded in developing gene therapy programs for Friedreich Ataxia⁶⁻⁸.

Ref: 1. Lescouzères and Bomont. *Front Physiol.* (2020); 2. Bomont et al., *Nat Genet* (2000); 3. Mahammad et al., *J Clin Invest* (2013)-leading group: RD. Goldman; 4. Scrivo et al., *Nat Commun* (2019); 5. Arribat, Mysiak et al., *J Clin Invest* (2019); 6. Perdomini et al., *Nat Med.* (2014); Piguët et al., *Mol Ther.* (2018); Belbellaa et al., *Hum Mol Genet.* (2019).

Profiles. 3 engineers (Bomont & Puccio); will work in close collaboration with other members of the teams. Mandatory for all: curious, enthusiastic & team player; prior experience with **mice**. Engineer 1 expertise: **behaviour**, preferably sensory-motor tests; cell culture and biochemical skills are assets but not required. Engineer 2 expertise: **histopathology**; cell culture/immunofluorescence is an asset. Engineer 3 expertise: skills in **molecular biology** techniques; immunofluorescence and histopathology are assets but not required. French speaking is NOT a requirement.

When/how to apply. **URGENT:** starting date in September 2021. Please send your application in a SINGLE 3 page-long pdf, including you CV, summary of your previous research experiences, and contact information of 2-3 references to: pascale.bomont@inserm.fr and helene.puccio@inserm.fr

Where. Bomont and Puccio teams are both at the NeuroMyoGene institute, located in the Rockefeller campus, in the highly dynamic and international city of Lyon, France. Lyon is considered as one of the most attractive metropolises in Europe, with a strong signature in biological science, architecture, & gastronomy.



Link to [Bomont](https://www.inmg.fr/bomont/?lang=en) webpage: <https://www.inmg.fr/bomont/?lang=en>

Link to [Puccio](https://www.inmg.fr/puccio/?lang=en) webpage: <https://www.inmg.fr/puccio/?lang=en>

